CRYSTALLINE (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2-METHYL-1,1-BIPHENYL-4-YL)CARBONYL]PYRROLIDIN-3-ONE O-METHYLOXIME USEFUL IN METHODS OF TREATING CONDITIONS RELATED TO THE OT-R ACTIVITY
Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2-methyl-1,1-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime is disclosed. A pharmaceutical composition containing the crystalline compound and methods for treating conditions related to the OT-R activity, such as preterm labor, and for increasing embryo implantation rate in a mammal undergoing embryo transfer, comprising administering the crystalline compound are also disclosed.Linvention concerne une O-méthyl-oxime de la (3Z,5S)-5-(hydroxyméthyl)-1-[(2-méthyl-1,1-biphényl-4-yl)carbonyl]pyrrolidin-3-one cristalline. Linvention concerne également une composition pharmaceutique contenant le composé cristallin et des méthodes de traitement détats liés à lactivité OT-R, tels que le travail prématuré, et daugmentation du taux dimplantation embryonnaire chez un mammifère soumis à un transfert dembryon, comprenant ladministration du composé cristallin.
